Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis
- PMID: 33217029
- DOI: 10.1111/jgh.15352
Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis
Abstract
Objective: While the global prevalence of antibiotic-resistant Helicobacter pylori (H. pylori) is increasing, there is much regional variation, and local data are required to guide eradication therapy. We performed a systematic review and meta-analysis to determine rates of H. pylori antibiotic resistance in Australia and New Zealand.
Study design: Random effects meta-analysis of data from 15 published studies and three published abstracts reporting prevalence of primary or secondary H. pylori antibiotic resistance in Australasia.
Data sources: PubMed, EMBASE, MEDLINE, PROSPERO, and the Cochrane Library were searched until August, 2020.
Data synthesis: Fifteen published studies and three published abstracts were identified; one study was excluded due to high risk of bias. Seventeen studies conducted between 1996 and 2013 were included in the final analysis, 12 reporting primary and five reporting secondary antibiotic resistance. Prevalence of primary resistance was clarithromycin 7.4% (95% confidence interval [CI], 5.3-9.7%), metronidazole 50.0% (95%CI, 23.9-56.1%), fluoroquinolones 3.7% (95%CI, 0.004-14.8%), and both amoxicillin and tetracycline <0.5%. Subgroup analysis (last 20 years) showed doubling of clarithromycin resistance to 16.1% (95%CI 11.2-21.7%) with other resistance stable. Prevalence of secondary resistance was high for all antibiotics, particularly clarithromycin 78.7% (95%CI, 64.1-90.1%) and metronidazole 68.3% (95%CI, 59.9-76.1%).
Conclusions: The outcomes reveal an increase in primary H. pylori clarithromycin resistance since the year 2000, while metronidazole resistance has remained stable and primary resistance to amoxicillin, tetracycline, and fluoroquinolones is low. Rates of secondary resistance to metronidazole and clarithromycin are high. The results highlight the need for contemporary local data on antibiotic resistance in Australia and New Zealand.
Keywords: Australia; Helicobacter pylori; New Zealand; antibiotic; antimicrobial; resistance.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2024 Jan;9(1):56-67. doi: 10.1016/S2468-1253(23)00281-9. Epub 2023 Nov 14. Lancet Gastroenterol Hepatol. 2024. PMID: 37972625
-
Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years.Intern Med J. 2022 Sep;52(9):1554-1560. doi: 10.1111/imj.15640. Epub 2022 Aug 19. Intern Med J. 2022. PMID: 34865299
-
ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE.Arq Gastroenterol. 2019 Oct-Dec;56(4):361-366. doi: 10.1590/S0004-2803.201900000-72. Arq Gastroenterol. 2019. PMID: 31721972
-
Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.Helicobacter. 2018 Dec;23(6):e12545. doi: 10.1111/hel.12545. Epub 2018 Oct 16. Helicobacter. 2018. PMID: 30324756
-
Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis.Am J Gastroenterol. 2022 Aug 1;117(8):1221-1230. doi: 10.14309/ajg.0000000000001828. Epub 2022 May 5. Am J Gastroenterol. 2022. PMID: 35509128
Cited by
-
Novel therapeutic regimens against Helicobacter pylori: an updated systematic review.Front Microbiol. 2024 Jun 7;15:1418129. doi: 10.3389/fmicb.2024.1418129. eCollection 2024. Front Microbiol. 2024. PMID: 38912349 Free PMC article. Review.
-
Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial.Evid Based Complement Alternat Med. 2022 Apr 7;2022:2266023. doi: 10.1155/2022/2266023. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35432566 Free PMC article.
-
Efficacy and safety of seven Chinese patent medicines combined with conventional triple/quadruple therapy for Helicobacter pylori-positive peptic ulcers: a systematic review and network meta-analysis.BMJ Open. 2024 Apr 29;14(4):e074188. doi: 10.1136/bmjopen-2023-074188. BMJ Open. 2024. PMID: 38684278 Free PMC article.
-
Geospatial analysis of Helicobacter pylori infection in South Australia: Should location influence eradication therapy?J Gastroenterol Hepatol. 2022 Jul;37(7):1263-1274. doi: 10.1111/jgh.15832. Epub 2022 Mar 31. J Gastroenterol Hepatol. 2022. PMID: 35315547 Free PMC article.
-
Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.Helicobacter. 2021 Oct;26(5):e12830. doi: 10.1111/hel.12830. Epub 2021 Jul 10. Helicobacter. 2021. PMID: 34247436 Free PMC article.
References
-
- Hooi JKY et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017; 153: 420-429.
-
- Moujaber T et al. The seroepidemiology of Helicobacter pylori infection in Australia. Int. J. Infect. Dis. 2008; 12: 500-504.
-
- Peach HG, Pearce DC, Farish SJ. Helicobacter pylori infection in an Australian regional city: prevalence and risk factors. Med. J. Aust. 1997; 167: 310-313.
-
- Robertson MS et al. Helicobacter pylori infection in the Australian community: current prevalence and lack of association with ABO blood groups. Intern. Med. J. 2003; 33: 163-167.
-
- Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin. Microbiol. Rev. 2010; 23: 713-739.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical